|High-risk HER2-positive Early-stage Breast Cancer(DESTINY-Breast11)
||A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan(T-DXd) Monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with High-risk HER2-positive Early-stage Breast Cancer(DESTINY-Breast11)
||A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies
||InnoCare Pharma Inc.
|Advanced Hepatocellular Carcinoma
||A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination with Nivolumab as a Second-line Treatment in Subjects with Advanced Hepatocellular Carcinoma
|This is 2L-4L study for patients with R/R MM.
||A Phase III Randomized, open-label trial of SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) in patients with relapsed or Refractory Multiple Myeloma(RRMM).
|First-line HER2-positive Breast Cancer (DESTINY-Breast09).
||A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in First-line HER2-positive Breast Cancer (DESTINY-Breast09).
|Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
||A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
|Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
||A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
|2 L and above any Lymphoid Malignancies
||An Open-Label, Phase 1/2 Study Evaluating AVM0703 in Patients with Lymphoid Malignancies (WWRD Study)
|advanced solid tumors with genomic alterations or protein expression patterns predictive of response
||An Open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response
|The first-line treatment of participants with extensive-stage small cell lung cancer
||Phase 3 Study of Chemotherapy with MK-7684A or Atezolizumab in First Line ES-SCLC
|Newly diagnosed diffuse large B-cell lymphoma (DLBCL)
||Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
|Advanced/Metastatic Non-small Cell Lung Cancer
||Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
|Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
||Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
||G1 Therapeutics Inc